Budget 2026: A Paradigm Shift for Cancer Care and Mental Health in India

Spread the Message

Read Time:4 Minute, 42 Second

February 2, 2026

NEW DELHI — In a landmark move to address India’s burgeoning non-communicable disease crisis, Union Finance Minister Nirmala Sitharaman on Sunday unveiled a series of high-impact health initiatives in the Union Budget 2026. The government has proposed a full customs duty waiver on 17 essential cancer drugs and expanded relief for seven rare diseases, while simultaneously announcing the establishment of NIMHANS-2 in North India—a move set to decentralize specialized psychiatric care in a region long underserved by national mental health infrastructure.

Easing the Economic Burden of Cancer and Rare Diseases

For millions of Indian families, a cancer diagnosis is often followed by a secondary crisis: financial toxicity. To combat this, the 2026 Budget provides a significant fiscal cushion by exempting 17 life-saving oncology medications from basic customs duty, which typically ranges from 7.5% to 10%.

“Basic customs duty on 17 drugs and medicines will be exempt to help reduce treatment costs,” Minister Sitharaman stated during her ninth Budget presentation. The exemption extends to medicines used in the treatment of various cancers, including advanced therapies that are currently not manufactured domestically.

Beyond oncology, the government has recognized the plight of those living with rare genetic disorders. Seven additional rare diseases will now be covered under duty exemptions for the personal import of specialized drugs and “Food for Special Medical Purposes” (FSMP). This expansion is a vital lifeline for patients whose survival depends on niche therapies that often carry exorbitant landed costs due to import levies.

Expert Perspective: A Step Toward Equity

“The removal of these duties is a compassionate and strategic intervention,” says Dr. Mandeep Singh Malhotra, Director of Surgical Oncology at CK Birla Hospital, Delhi. “By improving affordability for therapies not manufactured in India, we can ensure better clinical outcomes and more equitable access for patients who previously had to choose between life-saving treatment and financial ruin.”

Mental Health: Bridging the North-South Divide

Perhaps the most significant structural reform in this Budget is the proposal to establish NIMHANS-2 in North India. Currently, the National Institute of Mental Health and Neurosciences (NIMHANS) in Bengaluru stands as the country’s sole premier apex center for psychiatric care and research.

The lack of a comparable facility in the North has forced patients to travel thousands of kilometers for specialized neuro-psychiatric treatment. To further bolster regional care, the government will also upgrade the National Mental Health Institutes in Ranchi and Tezpur to Regional Apex Institutions.

Addressing the Treatment Gap

According to the National Mental Health Survey (NMHS), nearly 150 million Indians require mental health services, yet less than 30 million seek care. The “treatment gap” for common mental disorders in India is estimated to be as high as 80–85%.

Initiative	Objective	Key Focus Area
NIMHANS-2	Centralized Apex Care	North India Regional Access
Ranchi & Tezpur Upgrades	Decentralization	Eastern & North-Eastern Support
District Hospital Boost	50% Capacity Increase	Emergency & Trauma Care

“Mental health has long remained at the margins of public discourse,” notes Dr. Samir Parikh, Chairperson of the Mental Health Programme at Fortis Healthcare. “Establishing NIMHANS 2.0 signals a necessary recalibration of national priorities, acknowledging that mental well-being is fundamental to a productive society.”

Strengthening the “Last Mile”: Trauma and Disability Support

Recognizing that health shocks are a primary driver of poverty, the Finance Minister proposed a 50% capacity increase in district hospitals through the establishment of dedicated Emergency and Trauma Care Centres. These centers aim to provide immediate stabilization for accident victims and those facing acute psychiatric crises in rural areas.

Empowerment through Technology: Divyang Sahara Yojana

The Budget also introduced two flagship schemes for the Divyangjan (persons with disabilities):

Divyangjan Kaushal Yojana: Providing industry-relevant training in sectors like IT, hospitality, and gaming.
Divyang Sahara Yojana: Supporting the Artificial Limbs Manufacturing Corporation of India (ALIMCO) to scale up production using Artificial Intelligence (AI) and R&D for more ergonomic, high-quality assistive devices.

Limitations and Practical Considerations

While the medical fraternity has largely welcomed the duty waivers, some experts caution that the impact on retail prices may be moderated by other factors. “While the customs duty waiver is a victory for patients, we must ensure that the benefit is passed down entirely by distributors and hospitals,” explains a public health analyst. Additionally, the Budget did not provide specific timelines for the completion of NIMHANS-2, leaving questions about when Northern Indian patients will see the physical doors of the institute open.

Furthermore, while 17 drugs have been exempted, hundreds of other oncology medications remain subject to GST and other local taxes, suggesting that further policy shifts may be needed to achieve true “universal affordable cancer care.”

What This Means for You

For Cancer Patients: Expect a reduction in the “landed cost” of specific imported oncology drugs. Patients should consult their oncologists to see if their prescribed medication falls under the new exemption list.
For Rare Disease Families: Personal imports of specialized medical foods and drugs for seven new categories will now be significantly cheaper at the port of entry.
For North Indian Residents: Specialized psychiatric consultations and neuro-research will eventually be available closer to home, reducing the need for costly travel to Bengaluru.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.